The Gene expression Grade Index: A potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 198 trial

BMC Medical Genomics

Volumn 2, Issue , 2009, Pages

  Desmedt, Christine ^a   Giobbie Hurder, Anita ^b   Neven, Patrick ^c   Paridaens, Robert ^c   Christiaens, Marie Rose ^c   Smeets, Ann ^c   Lallemand, Françoise ^a   Haibe Kains, Benjamin ^a   Viale, Giuseppe ^d   Gelber, Richard D ^e   Piccart, Martine ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MONOTHERAPY; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 68149147400     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-2-40     Document Type: Article

References (16)

1. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? C Sotiriou MJ Piccart, Nat Rev Cancer 2007 7 545 553 10.1038/nrc2173 17585334 (Pubitemid 46985399)
2. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains C Desmedt D Larsimont F Cardoso H Peterse D Nuyten M Buyse MJ Van de Vijver J Bergh M Piccart M Delorenzi, J Natl Cancer Inst 2006 98 262 272 16478745
3. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. S Loi B Haibe-Kains C Desmedt F Lallemand AM Tutt C Gillet P Ellis A Harris J Bergh JA Foekens JG Klijn D Larsimont M Buyse G Bontempi M Delorenzi MJ Piccart C Sotiriou, J Clin Oncol 2007 25 1239 1246 10.1200/JCO.2006.07.1522 17401012 (Pubitemid 46640570)
4. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. F Boccardo A Rubagotti D Aldrighetti F Buzzi G Cruciani A Farris G Mustacchi M Porpiglia G Schieppati P Sismondi, Cancer 2007 109 1060 1067 10.1002/cncr.22513 17295293 (Pubitemid 46435383)
5. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 198. AS Coates A Keshaviah B Thürlimann H Mouridsen L Mauriac JF Forbes R Paridaens M Castiglione-Gertsch RD Gelber M Colleoni I Láng L Del Mastro I Smith J Chirgwin JM Nogaret T Pienkowski A Wardley EH Jakobsen KN Price A Goldhirsch, J Clin Oncol 2007 25 486 492 10.1200/JCO.2006.08.8617 17200148 (Pubitemid 350002953)
6. Survival and safety of exemestane versus tamoxifen after 23 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. RC Coombes LS Kilburn CF Snowdon R Paridaens RE Coleman SE Jones J Jassem CJ Van de Velde T Delozier I Alvarez L Del Mastro O Ortmann K Diedrich AS Coates E Bajetta SB Holmberg D Dodwell E Mickiewicz J Andersen PE Lønning G Cocconi J Forbes M Castiglione N Stuart A Stewart LJ Fallowfield G Bertelli E Hall RG Bogle M Carpentieri E Colajori M Subar E Ireland JM Bliss Intergroup Exemestane Study, Lancet 2007 369 559 570 10.1016/S0140-6736(07)60200-1 17307102 (Pubitemid 46251559)
7. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes G Hoctin-Boes J Houghton GY Locker JS Tobias ATAC Trialists' Group, Lancet 2005 365 60 62 10.1016/S0140-6736(05) 74803-0 15639680
8. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. W Jonat M Gnant F Boccardo M Kaufmann A Rubagotti I Zuna M Greenwood R Jakesz, Lancet Oncol 2006 7 991 996 10.1016/S1470-2045(06)70948-2 17138220 (Pubitemid 44804137)
9. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Breast International Group (BIG) 198 Collaborative Group B Thürlimann A Keshaviah AS Coates H Mouridsen L Mauriac JF Forbes R Paridaens M Castiglione-Gertsch RD Gelber M Rabaglio I Smith A Wardley KN Price A Goldhirsch, N Engl J Med 2005 353 2747 2457 10.1056/NEJMoa052258 16382061 (Pubitemid 43016814)
10. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 198 randomised trial. BB Rasmussen MM Regan AE Lykkesfeldt P Dell'Orto B Del Curto KL Henriksen MG Mastropasqua KN Price E Méry M Lacroix-Triki S Braye HJ Altermatt RD Gelber M Castiglione-Gertsch A Goldhirsch BA Gusterson B Thürlimann AS Coates G Viale BIG 198 Collaborative and International Breast Cancer Study Groups, Lancet Oncol 2008 9 23 28 10.1016/S1470-2045(07)70386-8 18083065
11. Survival model predictive accuracy and ROC curves. PJ Heagerty Y Zheng, Biometrics 2005 61 92 105 10.1111/j.0006-341X.2005.030814.x 15737082 (Pubitemid 40380968)
12. Introduction to risksetROC: An R Package for Riskset-ROC (Incident/Dynamic) Calculation. P Saha PJ Heagerty Y Zheng, http://faculty. washington.edu/heagerty/Software/SurvROC/
13. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. PE Goss JN Ingle S Martino NJ Robert HB Muss MJ Piccart M Castiglione D Tu LE Shepherd KI Pritchard RB Livingston NE Davidson L Norton EA Perez JS Abrams DA Cameron MJ Palmer JL Pater, J Natl Cancer Inst 2005 97 1262 1271 16145047
14. Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 198 Comparing Adjuvant Tamoxifen With Letrozole. G Viale A Giobbie-Hurder MM Regan AS Coates MG Mastropasqua P Dell'Orto E Maiorano G MacGrogan SG Braye C hlschlegel P Neven Z Orosz WP Olszewski F Knox B Thürlimann KN Price RD Castiglione-Gertsch Gelber BA Gusterson A Goldhirsch, J Clin Oncol 2008 26 5569 5575 10.1200/JCO.2008.17.0829 18981464
15. What do we know about the mechanisms of aromatase inhibitor resistance? S Chen S Masri X Wang S Phung YC Yuan W Xiwei, J Steroid Biochem Mol Biol 2006 102 232 240 17055257 10.1016/j.jsbmb.2006.09.012 (Pubitemid 44750638)
16. Letrozole-, Anastrozole-, and Tamoxifen-Responsive Genes in MCF-7aro Cells: A Microarray Approach. T Itoh K Karlsberg I Kijima YC Yuan D Smith J Ye S Chen, Mol Cancer Res 2005 4 203 218